Tailored combinations of tools are the way forward to assess quality of life in rare cancers
Recent studies emphasise that the current approach does not fully capture the needs and experiences of patients with rare tumours
Next-generation PRAME-directed TCR T-cell therapy shows early activity in solid tumours
Tumour reduction was observed with IMA203CD8 across different PRAME-expressing cancers in a phase I trial
Immunotherapy combinations enhance radiotherapy response in resectable sarcoma
Effective biomarkers and histology-focused enrichment trials are now needed to further improve patient outcomes
Telemedicine reduces delays in bone sarcoma management in rural India
A model implemented by a non-profit organisation exemplifies how virtual consultation and follow-up of patients with rare cancer can facilitate continuity of care
Rare cancers: research progresses at a slower pace than in other areas of oncology
With its new peer-reviewed journal dedicated to rare tumours, ESMO supports knowledge and data sharing among the stakeholders in the field
Regorafenib delays disease progression in patients with soft tissue sarcoma
Study findings indicate that the agent is promising as maintenance therapy, but managing its tolerability presents challenges
Some clinical activity was reported for novel tyrosine kinase inhibitors in previously treated patients with GIST
However, the future of TKI combinations for these rare tumours is uncertain
First gene engineered T-cell therapy for solid tumours confirmed to be a promising tool
The positive results of the SPEARHEAD-1 trial which showed durable responses of afamitresgene autoleucel in unresectable or metastatic synovial sarcoma granted FDA accelerated approval
Prolonged use of adjuvant imatinib shows promise in localised GIST
A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of care
Desmoid tumours: nirogacestat improves quality of life also in stable disease
In a post hoc analysis of the DeFi trial, a reduction in symptom burden was reported, with benefits occurring early in treated patients